Protocol: CDISCPILOT01
Population: Efficacy

Table 14-3.01
Primary Endpoint Analysis: ADAS Cog (11) - Change from Baseline to Week 24 - LOCF

		Placebo (N=79)	Xanomeline High Dose (N=74)	Xanomeline Low Dose (N=81)
Baseline				
n	79		74	81
Mean (SD)	24.1	(12.19)	21.3 (11.74)	24.4 (12.92)
Median (Range)	21.0	(5;61)	18.0 (3;57)	21.0 (5;57)
Week 24				
n	79		74	81
Mean (SD)	26.7	(13.79)	22.8 (12.48)	26.4 (13.18)
Median (Range)	24.0	(5;62)	20.0 (3;62)	25.0 (6;62)
Change from Baseline				
n	79		74	81
Mean (SD)	2.5	(5.80)	1.5 (4.26)	2.0 (5.55)
Median (Range)	2.0	(-11;16)	1.0 (-7;13)	2.0 (-11;17)
p-value(Dose Response) [1][2]			0.245	
p-value(Xan - Placebo) [1][3]			0.233	0.569
Diff of LS Means (SE)			-1.0 (0.84)	-0.5 (0.82)
95% CI			(-2.7;0.7)	(-2.1;1.1)
p-value(Xan High - Xan Low) [1][3]			0.520	
Diff of LS Means (SE)			-0.5 (0.84)	
95% CI			(-2.2;1.1)	

^[1] Based on Analysis of covariance (ANCOVA) model with treatment and site group as factors and baseline value as a covariate.

^[2] Test for a non-zero coefficient for treatment (dose) as a continuous variable

^[3] Pairwise comparison with treatment as a categorical variable: p-values without adjustment for multiple comparisons.